Navigation Links
Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Date:10/16/2007

d 345 patients received Zingo one to three minutes before undergoing medical procedures requiring venipuncture or IV line placement at the back of hand or antecubital fossa (crux of the elbow). The primary endpoint was pain upon needle insertion utilizing the VAS pain scale. Demographic characteristics and sites of administration were evenly distributed across treatment groups.

The mean pain score in the Zingo-treated patients was significantly lower than in the placebo group (p = 0.003). Zingo was also well tolerated. The most common skin assessment findings were redness (erythema), red dots (petechiae) and swelling (edema) at the site of administration. The incidence of adverse events with Zingo was no higher than with placebo.

About Zingo

Zingo is a ready-to-use, single-use, needle-free system that delivers sterile lidocaine powder into the skin and provides topical, local analgesia in one to three minutes after administration. This rapid onset, which may be especially useful in busy emergency room settings, means the product can be incorporated into a medical procedure allowing uninterrupted care, an important advantage over current options. In addition to the hospital setting, Zingo may be used in physicians' offices and clinical laboratories. Anesiva also intends to expand the product label beyond the pediatric population by filing an sNDA for Zingo in adults in early 2008.

About Anesiva and its Diverse Portfolio of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, to reduce pain associated with peripheral venous access procedures in children three to 18 years of age. The second product in Anesiva's pipeline, Adlea(TM) (formerly 4975), has been shown to reduce pain after only a
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... 2014 Reportbuyer.com has added a ... Transparent Plastics: Global Markets Outside North America ... INTRODUCTION This chapter provides a general ... goals and objectives, reasons for doing the ... and analyst credentials, and related reports published ...
(Date:8/30/2014)... ANDOVER, Mass. , Aug. 30, 2014   ... launch of Affiniti, a new ultrasound system ... overcome the demands of increasing patient volumes and cost ... Cardiology (ESC) Congress 2014 in Barcelona ... radiology/ultrasound departments facing more patients with fewer resources deliver ...
(Date:8/29/2014)... , Aug. 29, 2014 The clinical ... can be the difference between a product,s success or ... map and stratify KOL targets – and then to ... type of strong relationships upon which successful KOL engagement ... pharma companies have identified internal inconsistencies in their KOL ...
Breaking Medicine Technology:Rigid Transparent Plastics: Global Markets Outside North America 2Rigid Transparent Plastics: Global Markets Outside North America 3Rigid Transparent Plastics: Global Markets Outside North America 4Rigid Transparent Plastics: Global Markets Outside North America 5Rigid Transparent Plastics: Global Markets Outside North America 6Rigid Transparent Plastics: Global Markets Outside North America 7Rigid Transparent Plastics: Global Markets Outside North America 8Rigid Transparent Plastics: Global Markets Outside North America 9Rigid Transparent Plastics: Global Markets Outside North America 10Rigid Transparent Plastics: Global Markets Outside North America 11Rigid Transparent Plastics: Global Markets Outside North America 12Rigid Transparent Plastics: Global Markets Outside North America 13Rigid Transparent Plastics: Global Markets Outside North America 14Rigid Transparent Plastics: Global Markets Outside North America 15Rigid Transparent Plastics: Global Markets Outside North America 16Rigid Transparent Plastics: Global Markets Outside North America 17Rigid Transparent Plastics: Global Markets Outside North America 18Rigid Transparent Plastics: Global Markets Outside North America 19Rigid Transparent Plastics: Global Markets Outside North America 20Rigid Transparent Plastics: Global Markets Outside North America 21Rigid Transparent Plastics: Global Markets Outside North America 22Rigid Transparent Plastics: Global Markets Outside North America 23Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4Implementing a Strategic Thought Leader Management & Engagement System 2
... Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, ... Capital Markets 6th Annual Healthcare Conference on November 17, 2009 ... New York City. Dr. Fernandes will provide an overview ... treatment of drug-resistant pathogens including MRSA. , About Cempra ...
... Nov. 13 Warner Chilcott plc (Nasdaq: WCRX ... its ordinary shares by certain selling shareholders. The ... DLJ Merchant Banking, J.P. Morgan Partners (advised by CCMP ... institutional investors and members of the Company,s senior management. ...
Cached Medicine Technology:Warner Chilcott Announces Secondary Equity Offering 2Warner Chilcott Announces Secondary Equity Offering 3Warner Chilcott Announces Secondary Equity Offering 4
(Date:9/1/2014)... Texas (PRWEB) September 02, 2014 Renal cell ... in the lining of the proximal convoluted tubule, a part ... waste molecules from the blood to the urine. The condition ... people with RCC are often in the advanced stages of ... symptoms of RCC often include blood in the urine, flank ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Liver is the ... vital organ that helps the body in barring itself from ... store of energy. Liver also plays many important functions such ... and glucose. , Many illnesses can affect the liver, ... the rib cage on the right side of the abdomen, ...
(Date:9/1/2014)... "Women struggle with weight gain typically associated to ... early as 15, if not earlier. Women therefore ... downs of hormone related weight gain. The battle ... to rage against the hidden and ever-present hormones which ... begin to face menopause and related changes, these hormonal ...
(Date:9/1/2014)... 1 September 2014: Permanent atrial fibrillation (AF) doubles the ... research in more than 6 000 patients presented at ... The findings suggest that a simple clinical assessment of ... estimate stroke risk. , Ischaemic stroke is the second ... a million deaths and many more disabled patients each ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
Breaking Medicine News(10 mins):Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 2Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 3Health News:Renal Cell Carcinoma Market Analysis & Epidemiology Forecast to 2023 Says a New Report Available at MarketOptimizer.org 4Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4
... $2.65 million to support San Jose Unified School District, ... Children,s,Hospital and the Lucile Packard Foundation for Children,s Health ... years to the San Jose,Unified School District. This ,demonstration ... located in neighborhoods,where many children lack access to regular ...
... Ala., Nov. 5 Southern Research,Institute, a ... in the areas of preclinical drug discovery, ... energy production,today announced the appointment of Vladimir ... Research Dept. in Birmingham., (Photo: ...
... mass, high levels of good cholesterol combat cardiovascular disease, ... -- Breast-fed babies are less likely than bottle-fed infants ... adulthood, say U.S. researchers who analyzed two generations of ... breast-fed in infancy is associated with a lower average ...
... of choice to manage abnormal heart rhythms, a new ... School of Medicine suggests that women with ICDs fare ... retrospective analysis to be presented at the AHA Scientific ... p.m.), lead researcher Andrea Russo, M.D., Clinical Associate Professor ...
... IRVING, Texas, Nov. 5 Carrington,Laboratories, Inc. (OTC ... DelSite Biotechnologies, Inc., its wholly-owned subsidiary,will be webcast ... Acumen BioFin Rodman &,Renshaw 9th Annual Healthcare Conference ... 7th, at 2:00 pm Eastern Time. The ...
... Nov. 5 - Players for the NFL,s,Chicago Bears will ... Chicago VA medical center, as part of the Disabled ... to visit the hospital at 2:30 p.m., to honor,veterans ... souvenirs, and helping brighten the day for those who ...
Cached Medicine News:Health News:Packard Children's Hospital, Foundation Provide Financial Support for School Nurses in San Jose 2Health News:Packard Children's Hospital, Foundation Provide Financial Support for School Nurses in San Jose 3Health News:Packard Children's Hospital, Foundation Provide Financial Support for School Nurses in San Jose 4Health News:Southern Research Institute Names Vladimir Yamshchikov Director of Infectious Disease Research Department in Birmingham 2Health News:Breast-Feeding Confers Long-Term Heart Benefits 2Health News:Do women fare worse with some heart devices? 2Health News:Carrington's DelSite Presentation at Rodman & Renshaw Conference to be Webcast Live on November 7th 2
... is the only handheld non-contact tonometer with over ... streamlined, quiet and now, with constant puff ... gentle puff of air. You can prove how ... the patient's hand before you start. With ...
... The Emit 2000 Phenytoin ... immunoassay intended for use in ... in human serum or plasma. ... use on the Roche COBAS ...
Our high quality therapeutic drug monitoring reagents, calibrators and controls are available for most chemistry analyzers. Reproducible and accurate results for your laboratory needs....
The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of digoxin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartridges ...
Medicine Products: